PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of this study was to assess the clinical impact of hand-foot syndrome (HFS) during treatment with two multikinase inhibitors, sorafenib and lenvatinib, in a large group of patients with advanced thyroid cancer. Moreover, we looked for possible associations between HFS occurrence and clinical and pathological features.
UNASSIGNED: We retrospectively evaluated 239 patients with advanced thyroid cancer: 165 treated with lenvatinib and 74 with sorafenib. Statistical analyses were performed to verify which features could be correlated with HFS development.
UNASSIGNED: HFS was observed in 35/74 (47.4%) and in 43/165 (26.7%) patients treated with sorafenib or lenvatinib, respectively. The median latency from the drug beginning and HFS appearance was 27 days for sorafenib and 2.9 months for lenvatinib. G3/G4 toxicity was observed in 16/35 (45.7%) patients treated with sorafenib and only in 3/43 (7%) treated with lenvatinib. Drug dose reduction due to HFS was required in 19/74 (25.7%) and 3/165 (1.8%) patients treated with sorafenib and lenvatinib, respectively. HFS occurrence was significantly associated with a longer duration of therapy in both groups.
UNASSIGNED: HFS was a frequent adverse event during both lenvatinib and sorafenib therapy, with a higher frequency and toxicity grade during sorafenib treatment. HFS was the most frequent reason for drug reduction or discontinuation in patient treated with sorafenib. Early diagnosis of HFS is important to allow early intervention, possibly in a multidisciplinary setting, and to avoid treatment discontinuation, which is highly relevant to obtain the maximum effectiveness of systemic therapy.
UNASSIGNED: We retrospectively evaluated 239 patients with advanced thyroid cancer: 165 treated with lenvatinib and 74 with sorafenib. Statistical analyses were performed to verify which features could be correlated with HFS development.
UNASSIGNED: HFS was observed in 35/74 (47.4%) and in 43/165 (26.7%) patients treated with sorafenib or lenvatinib, respectively. The median latency from the drug beginning and HFS appearance was 27 days for sorafenib and 2.9 months for lenvatinib. G3/G4 toxicity was observed in 16/35 (45.7%) patients treated with sorafenib and only in 3/43 (7%) treated with lenvatinib. Drug dose reduction due to HFS was required in 19/74 (25.7%) and 3/165 (1.8%) patients treated with sorafenib and lenvatinib, respectively. HFS occurrence was significantly associated with a longer duration of therapy in both groups.
UNASSIGNED: HFS was a frequent adverse event during both lenvatinib and sorafenib therapy, with a higher frequency and toxicity grade during sorafenib treatment. HFS was the most frequent reason for drug reduction or discontinuation in patient treated with sorafenib. Early diagnosis of HFS is important to allow early intervention, possibly in a multidisciplinary setting, and to avoid treatment discontinuation, which is highly relevant to obtain the maximum effectiveness of systemic therapy.
摘要：
目的：本研究的目的是评估两种多激酶抑制剂治疗期间手足综合征（HFS）的临床影响，索拉非尼和乐伐替尼，在一大群晚期甲状腺癌患者中。此外，我们寻找HFS发生与临床和病理特征之间可能的关联.
方法：我们回顾性评估了239例晚期甲状腺癌患者：165例接受lenvatinib治疗，74例接受索拉非尼治疗。进行统计分析以验证哪些特征可能与HFS发展相关。
结果：在35/74（47.4％）和43/165（26.7％）接受索拉非尼或乐伐替尼治疗的患者中观察到HFS，分别。从药物开始和HFS出现的中位潜伏期为索拉非尼27天，乐伐替尼2.9个月。在16/35（45.7％）接受索拉非尼治疗的患者中观察到G3/G4毒性，仅在3/43（7％）接受乐伐替尼治疗的患者中观察到。使用索拉非尼和乐伐替尼治疗的19/74（25.7％）和3/165（1.8％）患者由于HFS需要减少药物剂量，分别。两组HFS的发生与治疗持续时间的延长显着相关。
结论：在乐伐替尼和索拉非尼治疗期间，HFS是常见的不良事件，在索拉非尼治疗期间具有更高的频率和毒性等级。HFS是索拉非尼治疗患者减少或停药的最常见原因。HFS的早期诊断对于早期干预很重要。可能在多学科环境中，为了避免治疗中断，这与获得系统治疗的最大有效性高度相关。
方法：我们回顾性评估了239例晚期甲状腺癌患者：165例接受lenvatinib治疗，74例接受索拉非尼治疗。进行统计分析以验证哪些特征可能与HFS发展相关。
结果：在35/74（47.4％）和43/165（26.7％）接受索拉非尼或乐伐替尼治疗的患者中观察到HFS，分别。从药物开始和HFS出现的中位潜伏期为索拉非尼27天，乐伐替尼2.9个月。在16/35（45.7％）接受索拉非尼治疗的患者中观察到G3/G4毒性，仅在3/43（7％）接受乐伐替尼治疗的患者中观察到。使用索拉非尼和乐伐替尼治疗的19/74（25.7％）和3/165（1.8％）患者由于HFS需要减少药物剂量，分别。两组HFS的发生与治疗持续时间的延长显着相关。
结论：在乐伐替尼和索拉非尼治疗期间，HFS是常见的不良事件，在索拉非尼治疗期间具有更高的频率和毒性等级。HFS是索拉非尼治疗患者减少或停药的最常见原因。HFS的早期诊断对于早期干预很重要。可能在多学科环境中，为了避免治疗中断，这与获得系统治疗的最大有效性高度相关。
